Skip to main content
Top
Published in: BMC Medical Research Methodology 1/2021

Open Access 01-12-2021 | HIV Drug | Research article

Guidelines are needed for studies of pre-treatment HIV drug resistance: a methodological study

Authors: Lawrence Mbuagbaw, Clémence Ongolo-Zogo, Olivia C. Mendoza, Babalwa Zani, Frederick Morfaw, Agatha Nyambi, Annie Wang, Michel Kiflen, Hussein El-Kechen, Alvin Leenus, Mark Youssef, Nadia Rehman, Lucas Hermans, Virginia MacDonald, Silvia Bertagnolio

Published in: BMC Medical Research Methodology | Issue 1/2021

Login to get access

Abstract

Background

The expansion of access to antiretroviral therapy (ART) has been accompanied by an increase in pre-treatment drug resistance (PDR). While it is critical to monitor the increasing prevalence of PDR across countries and populations to inform optimal regimen selection, the completeness of reporting is often suboptimal, limiting the interpretation and generalizability of the results. Indeed, there is no formal guidance on how studies investigating the prevalence of drug resistance should be reported. Thus, we sought to determine the completeness of reporting in studies of PDR and the factors associated with sub-optimal reporting to ascertain the need for guidelines.

Methods

As part of a systematic review on the global prevalence of PDR in key populations (men who have sex with men, sex workers, transgender people, people who inject drugs and people in prisons), we searched 10 electronic databases until January 2019. We extracted information on selected study characteristics useful for interpreting prevalence data. Data were extracted in duplicate. Analyses of variance and correlation were used to explore factors that may explain the number of items reported.

Results

We found 650 studies of which 387 were screened as full text and 234 were deemed eligible. The included studies were published between 1997 and 2019 and included a median of 239 (quartile 1 = 101; quartile 3 = 778) participants. Most studies originated from high-income countries (125/234; 53.0%). Of 23 relevant data items, including study design, setting, participant sociodemographic characteristics, HIV risk factors, type of resistance test conducted, definition of resistance, the mean (standard deviation) number of items reported was 13 (2.2). We found that more items were reported in studies published more recently (r = 0.20; p < 0.002) and in studies at low risk of bias (F [2231] = 8.142; p < 0.001).

Conclusions

Incomplete reporting in studies on PDR makes characterising levels of PDR in subpopulations across countries challenging. Hence, guidelines are needed to define a minimum set of variables to be included in such studies.
Appendix
Available only for authorised users
Literature
7.
go back to reference Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2017. Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2017.
11.
go back to reference Novak RM, Chen L, MacArthur RD, Baxter JD, Huppler Hullsiek K, Peng G, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis. 2005;40(3):468–74. https://doi.org/10.1086/427212.CrossRefPubMed Novak RM, Chen L, MacArthur RD, Baxter JD, Huppler Hullsiek K, Peng G, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis. 2005;40(3):468–74. https://​doi.​org/​10.​1086/​427212.CrossRefPubMed
12.
go back to reference Sullivan A, Sutcliffe PS, re R, Harrigan PR, Archibald C, Halverson J, et al. follow-up investigation of a cluster of treatment-naive HIV-infected patients with multi-drug resistance in Sudbury, Ontario. Can J Infect Dis Med Microbiol. 2013;24:38A.CrossRef Sullivan A, Sutcliffe PS, re R, Harrigan PR, Archibald C, Halverson J, et al. follow-up investigation of a cluster of treatment-naive HIV-infected patients with multi-drug resistance in Sudbury, Ontario. Can J Infect Dis Med Microbiol. 2013;24:38A.CrossRef
14.
go back to reference MacDonald V, Mbuagbaw L, Verster A, Bertagnolio S. Alarming rates of pretreatment HIV drug resistance in key populations: Results of a global systematic review. In: 22nd International AIDS Conference. Amsterdam, the Netherlands: WEPEB13; 2018. MacDonald V, Mbuagbaw L, Verster A, Bertagnolio S. Alarming rates of pretreatment HIV drug resistance in key populations: Results of a global systematic review. In: 22nd International AIDS Conference. Amsterdam, the Netherlands: WEPEB13; 2018.
18.
go back to reference McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22(3):276–82.CrossRef McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22(3):276–82.CrossRef
23.
go back to reference Samaan Z, Mbuagbaw L, Kosa D, Debono VB, Dillenburg R, Zhang S, et al. A systematic scoping review of adherence to reporting guidelines in health care literature. J Multidiscip Healthc. 2013;6:169.PubMedPubMedCentral Samaan Z, Mbuagbaw L, Kosa D, Debono VB, Dillenburg R, Zhang S, et al. A systematic scoping review of adherence to reporting guidelines in health care literature. J Multidiscip Healthc. 2013;6:169.PubMedPubMedCentral
25.
go back to reference Jiamsakul A, Chaiwarith R, Durier N, Sirivichayakul S, Kiertiburanakul S, Van Den Eede P, et al. Comparison of genotypic and virtual phenotypic drug resistance interpretations with laboratory-based phenotypes among CRF01_AE and subtype B HIV-infected individuals. J Med Virol. 2016;88(2):234–43. https://doi.org/10.1002/jmv.24320.CrossRefPubMed Jiamsakul A, Chaiwarith R, Durier N, Sirivichayakul S, Kiertiburanakul S, Van Den Eede P, et al. Comparison of genotypic and virtual phenotypic drug resistance interpretations with laboratory-based phenotypes among CRF01_AE and subtype B HIV-infected individuals. J Med Virol. 2016;88(2):234–43. https://​doi.​org/​10.​1002/​jmv.​24320.CrossRefPubMed
27.
go back to reference Wensing AM, Calvez V, Ceccherini-Silberstein F, Charpentier C, Günthard HF, Paredes R, et al. 2019 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2019;27(3):111–21.PubMedPubMedCentral Wensing AM, Calvez V, Ceccherini-Silberstein F, Charpentier C, Günthard HF, Paredes R, et al. 2019 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2019;27(3):111–21.PubMedPubMedCentral
29.
go back to reference Burchell AN, Gardner S, Light L, Ellis BM, Antoniou T, Bacon J, et al. Implementation and operational research: engagement in HIV care among persons enrolled in a clinical HIV cohort in Ontario, Canada, 2001–2011. J Acquir Immune Defic Syndr (1999). 2015;70(1):e10–9.CrossRef Burchell AN, Gardner S, Light L, Ellis BM, Antoniou T, Bacon J, et al. Implementation and operational research: engagement in HIV care among persons enrolled in a clinical HIV cohort in Ontario, Canada, 2001–2011. J Acquir Immune Defic Syndr (1999). 2015;70(1):e10–9.CrossRef
31.
go back to reference Lunar MM, Židovec LS, Abecasis AB, Tomažič J, Vidmar L, et al. Short communication: prevalence of HIV type 1 transmitted drug resistance in Slovenia: 2005-2010. AIDS Res Hum Retrovir. 2013;29(2):343–9.CrossRef Lunar MM, Židovec LS, Abecasis AB, Tomažič J, Vidmar L, et al. Short communication: prevalence of HIV type 1 transmitted drug resistance in Slovenia: 2005-2010. AIDS Res Hum Retrovir. 2013;29(2):343–9.CrossRef
Metadata
Title
Guidelines are needed for studies of pre-treatment HIV drug resistance: a methodological study
Authors
Lawrence Mbuagbaw
Clémence Ongolo-Zogo
Olivia C. Mendoza
Babalwa Zani
Frederick Morfaw
Agatha Nyambi
Annie Wang
Michel Kiflen
Hussein El-Kechen
Alvin Leenus
Mark Youssef
Nadia Rehman
Lucas Hermans
Virginia MacDonald
Silvia Bertagnolio
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Medical Research Methodology / Issue 1/2021
Electronic ISSN: 1471-2288
DOI
https://doi.org/10.1186/s12874-021-01258-1

Other articles of this Issue 1/2021

BMC Medical Research Methodology 1/2021 Go to the issue